Cipla has reported a surge of 17.03% in its net profit at Rs 1123.96 crore for the year ended March 31, 2012, against Rs 960.39 crore for the corresponding period last fiscal. Total income increased by 10.95% at Rs 7125.80 crore during the year under review from Rs 6422.73 crore in the year-ago period.
On consolidated basis, the company has posted a rise of 15.63% in its net profit at Rs 1144.24 crore for the year ended March 31, 2012 as compared to Rs 989.57 crore for the same period in the previous year. Total income has increased by 11.61% at Rs 7160.23 crore for year under review as compared to Rs 6415.52 crore for the period ended March 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1903.00 |
| Dr. Reddys Labs. | 1353.75 |
| Cipla | 1452.35 |
| Zydus Lifesciences | 1152.90 |
| Lupin | 2489.85 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: